These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 21521416

  • 1. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
    Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.
    Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
    [Abstract] [Full Text] [Related]

  • 2. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY.
    Lung Cancer; 2008 Feb 01; 59(2):180-91. PubMed ID: 17900752
    [Abstract] [Full Text] [Related]

  • 4. Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.
    Kumar VB, Yuan TC, Liou JW, Yang CJ, Sung PJ, Weng CF.
    Mutat Res; 2011 Feb 10; 707(1-2):42-52. PubMed ID: 21185843
    [Abstract] [Full Text] [Related]

  • 5. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X, Zhan Y, Zhao L, Alvarez J, Chaudhary I, Zhou BB, Abraham RT, Feuerstein GZ.
    J Pharmacol Exp Ther; 2011 Nov 10; 339(2):421-9. PubMed ID: 21835932
    [Abstract] [Full Text] [Related]

  • 6. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 10; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 7. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
    Mauceri HJ, Sutton HG, Darga TE, Kocherginsky M, Kochanski J, Weichselbaum RR, Vokes EE.
    Oncol Rep; 2012 May 10; 27(5):1625-9. PubMed ID: 22294050
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O.
    J Thorac Cardiovasc Surg; 2012 Nov 10; 144(5):1167-1175.e1. PubMed ID: 22925564
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M, Yamada T, Tamura M, Ishikawa D, Hoda MA, Matsumoto I, Klepetko W, Oda M, Yano S, Watanabe G.
    Oncol Rep; 2014 Mar 10; 31(3):1109-15. PubMed ID: 24378576
    [Abstract] [Full Text] [Related]

  • 10. Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.
    Kong M, Fan J, Dong A, Cheng H, Xu R.
    Acta Biochim Biophys Sin (Shanghai); 2010 Nov 10; 42(11):827-33. PubMed ID: 20978038
    [Abstract] [Full Text] [Related]

  • 11. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
    Nishikawa T, Takaoka M, Ohara T, Tomono Y, Hao H, Bao X, Fukazawa T, Wang Z, Sakurama K, Fujiwara Y, Motoki T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.
    Cancer Biol Ther; 2013 Mar 10; 14(3):230-6. PubMed ID: 23291985
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
    Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N.
    BMC Cancer; 2007 Jan 12; 7():8. PubMed ID: 17222343
    [Abstract] [Full Text] [Related]

  • 13. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC, Schaefer E, Christensen JG, Salgia R.
    Clin Cancer Res; 2005 Mar 15; 11(6):2312-9. PubMed ID: 15788682
    [Abstract] [Full Text] [Related]

  • 14. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.
    Oncogene; 2006 Jun 01; 25(23):3335-45. PubMed ID: 16462770
    [Abstract] [Full Text] [Related]

  • 15. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C, Maione P, Rossi A.
    Oncologist; 2008 Feb 01; 13(2):139-47. PubMed ID: 18305058
    [Abstract] [Full Text] [Related]

  • 16. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.
    Cancer Res; 2008 Apr 15; 68(8):2934-43. PubMed ID: 18413763
    [Abstract] [Full Text] [Related]

  • 17. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A.
    Exp Hematol; 2008 Apr 15; 36(4):443-50. PubMed ID: 18343280
    [Abstract] [Full Text] [Related]

  • 18. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.
    Chen Z, Huang X, Yang H, Ding W, Gao L, Ye Z, Zhang Y, Yu Y, Lou Y.
    Chem Biol Interact; 2011 Jan 15; 189(1-2):90-9. PubMed ID: 21075094
    [Abstract] [Full Text] [Related]

  • 20. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.